14 August 2025

The UKKA invites feedback on a newly released draft clinical guideline aimed at standardising the initial immunosuppressive treatment of immune mediated glomerular diseases (IM-GD) in children and young people (CYP) across the UK.

The draft guideline outlines national recommendations for the early treatment of IM-GD in CYP, including both induction and consolidation immunosuppressive therapy strategies. The recommendations seek to align UK paediatric nephrology practice with the latest evidence and international standards while ensuring consistency and equity in care delivery.

The draft guideline is now open for consultation, and BAPN members are strongly encouraged to review and provide feedback.

🔗 Access the Draft Guideline and Comments Form Here

📅 Deadline for feedback submission: Monday, 9 September 2025
📧 Please return completed comments forms to: ukka@ukkidney.org

Aims of the Guideline

The overarching goal of this guidance is to establish a unified, paediatric-specific approach to the immunosuppressive treatment of IM-GD that is aligned with existing international guidelines and the latest evidence. This will aspire to improve the quality of care and reduce unwarranted variation across the UK in the treatment administered to CYP with IM-GD through these agreed standard treatment plans.

Key Objectives of the Programme:

  • Review of current UK practice in the management of paediatric IM-GD in line with internationally accepted speciality guidelines

  • Systematic summary of available evidence on immunosuppressive therapies in CYP with IM-GD

  • Development of best practice recommendations for:

    • Induction treatment: Aimed at achieving disease remission shortly after diagnosis

    • Consolidation treatment: Aimed at maintaining remission over the first 12 months post-diagnosis

Get Involved

Your clinical expertise and frontline experience are vital to ensure the final guideline is practical, evidence-based, and applicable to real-world paediatric nephrology settings. We encourage all members of BAPN, particularly those involved in the treatment of glomerular diseases, to engage with this important consultation process.

Please ensure your feedback is submitted by 9 September 2025 to help shape the final version of this guideline.

For further information or questions regarding the guideline or the consultation process, contact: ukka@ukkidney.org